Nurexone Biologic Inc (<a href= "https://www.otcmarkets.com/stock/NRXBF/quote" target="_blank" rel= "noopener">OTCQB: NRXBF</a>) is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Lior Shaltiel, CEO of Nurexone Biologic, joins us today to share and explain Nurexone's innovative and promising research on its lead candidate, XOP10. <a href= "https://www.otcmarkets.com/files/OTCQBPodcast_NurexoneBiologicInc_Season9Episode11.pdf" target="_blank" rel="noopener">View Podcast Transcript</a>

Nurexone Biologic Inc (OTCQB: NRXBF) is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Lior Shaltiel, CEO of Nurexone Biologic, joins us today to share and explain Nurexone's innovative and promising research on its lead candidate, XOP10. View Podcast Transcript

Nurexone Biologic Inc (<a href="https://www.otcmarkets.com/stock/NRXBF/quote" rel="noopener noreferrer">OTCQB: NRXBF</a>) is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Lior Shaltiel, CEO of Nurexone Biologic, joins us today to share and explain Nurexone's innovative and promising research on its lead candidate, XOP10. <a href="https://www.otcmarkets.com/files/OTCQBPodcast_NurexoneBiologicInc_Season9Episode11.pdf" rel="noopener noreferrer">View Podcast Transcript</a>

Nurexone Biologic Inc

OTC Markets presents our podcast series on the OTCQB Market, where we interview the entrepreneurs behind the companies that trade on the venture market.

Share Nurexone Biologic Inc

Sign up to save your podcasts

Nurexone Biologic Inc

Nurexone Biologic Inc